Analysts Raise Nuvation Bio 2026 Revenue Forecast 15.6%, Q1 Seen at $62.3M
NUVB•Nuvation Bio is projected to report Q1 revenue of $62.3M and EPS of $0.01 on May 4, following a Q4 beat with $41.9M revenue but a $0.11 loss per share. Analysts have lifted 2026 sales forecasts by 15.6% to $190.2M while trimming 2027 revenue outlook to $293.2M.
1. Q1 2026 Earnings Outlook
Nuvation Bio will release its Q1 2026 report on May 4, with consensus estimates at $62.26 million in revenue and $0.01 earnings per share, marking its first potentially positive quarterly EPS.
2. Full-Year 2026 Forecast Revisions
Revenue forecasts for 2026 have been raised from $164.48 million to $190.20 million over the past 90 days, while full-year EPS estimates improved from a loss of $0.52 per share to a $0.48 per share loss.
3. 2027 Outlook Cut
Analysts have trimmed 2027 revenue projections by 11.2%, from $329.86 million to $293.21 million, and lowered EPS forecasts from a $0.11 loss to a $0.27 loss per share.
4. Recent Performance & Analyst Targets
In Q4 2025, Nuvation Bio posted $41.87 million in revenue, beating estimates by 12.2%, but reported a $0.11 per share loss, triggering a 25.3% one-day stock drop. The average one-year price target is $11.60, implying 160.7% upside, with a consensus 'Outperform' rating.
